Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Exercise Rehab; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions: Low-dose aspirin, Placebo; Drug
Lead sponsor: Malamo Countouris; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: PAH
Interventions: oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Preeclampsia
Interventions: Delivery of infant; Procedure
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension, Obesity, Type 2 Diabetes, Insulin Resistance
Interventions: EGCG; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more

Conditions: Hypertension
Interventions: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension
Interventions: Weekly check-in; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: Hypercholesterolemia, Hypertension, Depression, Diabetes Mellitus, Type 2
Interventions: Health at Every Size (HAES), Diet (Traditional, moderate energy restriction); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 30 Years to 45 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 2
States / cities: Davis, California

Conditions: Hypertension
Interventions: Positive Affect/Self-Affirmation/Motivational Interviewing, Educational and Behavioral; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Interventions: Diltiazem Hydrochloride, Sugar Pill; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Disease
Interventions: Treatment as usual (TAU) + Internet, TAU + ElderTree; Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Preeclampsia, Anxiety, Hypertension, Pregnancy, Eclampsia, HELLP
Interventions: Graphic card, Video; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Danville, Pennsylvania • Forty Fort, Pennsylvania

Conditions: Diabetes, Depression, Insomnia, Hypertension
Interventions: Intervention arm - automated call and phone-based pharmacist counseling; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 38,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Selective laser trabeculoplasty; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 30 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pre-Eclampsia, Morbid Obesity, Parturient, Blood Pressure
Interventions: Non-invasive BP recording with conical Ultracheck Curve BP cuff, Non-invasive BP recording with traditional cylindrical BP cuff, Direct invasive arterial pressure; Device · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1976 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Interventions: tadalafil and ambrisentan upfront combination therapy; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension in Pregnancy
Interventions: Remote (text based) surveillance; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Call-Center Directed (CCD) Weight Loss Program, In-Person Directed (IPD) Weight Loss Program, Self-Directed Weight Loss Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

miRNA and Myokines in Patients With PAH

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Treatment With Aspirin After Preeclampsia: TAP Trial

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Mild Preeclampsia Near Term: Deliver or Deliberate?

Effect of EGCG on the Body's Response to Insulin

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Improving Adherence to Home Blood Pressure Monitoring With Pharmacist Support

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model

Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Multiple Chronic Conditions for Older Adults

Comparing Different Methods of Patient Education on Preeclampsia

e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Prevalence of Dyschromatopsia in Glaucoma Patients

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient With Severe Preeclampsia

Pigment Dispersion Syndrome With and Without Glaucoma

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

Remote Surveillance of Postpartum Hypertension

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)